Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin
that delivers a synergistic 5: 1 drug ratio into leukemia cells to a greater extent than normal …

Background Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …

BACKGROUND CPX‐351 is a liposome‐encapsulated fixed‐molar‐ratio formulation of
cytarabine and daunorubicin that exploits molar ratio–dependent drug‐drug synergy to …

CPX-351 is a liposomal formulation of cytarabine: daunorubicin designed to deliver
synergistic drug ratios to leukemia cells. In this phase 2 study, newly diagnosed older acute …

Purpose This phase I dose-escalation trial was performed to determine the maximum-
tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-351. Patients and …

Abstract On June 28, 2018, the Committee for Medicinal Products for Human Use adopted a
positive opinion, recommending the granting of a marketing authorization for the medicinal …

Abstract On August 3, 2017, the FDA granted regular approval to Vyxeos (also known as
CPX-351; Jazz Pharmaceuticals), a liposomal formulation of daunorubicin and cytarabine in …

Forty-eight patients received CPX-351 (liposome-encapsulated cytarabine: daunorubicin at
a 5: 1 molar ratio) every other day for 3 doses at 10 dose levels. Pharmacokinetic …

VYXEOS™ is a liposomal-encapsulated formulation of daunorubicin and cytarabine
delivering a fixed, synergistic 1: 5 molar ratio (hereafter referred to as daunorubicin …

For decades, the standard induction for patients with acute myeloid leukemia (AML) has
been the combination of cytarabine with anthracycline (7+ 3 regimen). In August 2017 the …